# Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older

> **NCT01878825** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 121 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Fluviral™

## Key facts

- **NCT ID:** NCT01878825
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-18
- **Primary completion:** 2013-08-09
- **Final completion:** 2013-08-09
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2018-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01878825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01878825, "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01878825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*